ABSTRACT
OBJECTIVES: Three iron chelators are used to treat transfusion-dependent beta-thalassemia: desferrioxamine (DFO), deferasirox (DFX), and deferiprone (DFP). Compliance is low for DFO as it cannot be administered orally. Combined administration of DFP and DFX is orally available, however, the therapeutic mechanism is unknown. This pilot study investigated the iron removal mechanisms of DFX and DFP treatment in patients with transfusion-dependent thalassemia major. METHODS: Each patient received three treatments sequentially: (1) DFX monotherapy, (2) DFP monotherapy, and (3) DFX/DFP combination therapy with a four-day washout period between each treatment. Urine and stool specimens were collected to determine the primary outcome of iron excretion volumes. RESULTS: The mean iron excretion was seven times higher after combination therapy with DFX and DFP. Monotherapies also increased excretions volumes, though to a significantly lesser degree. Combined administration of DFX and DFP achieves maximum iron removal in transfusion-dependent thalassemia major compared to monotherapy with either drug. CONCLUSIONS: We suggest combination therapy in chronic severe iron overload cases, especially for patients in poor compliance with DFO/DFP combination therapy or those exhibiting poor iron removal from DFX or DFP monotherapy.
Subject(s)
Deferasirox/therapeutic use , Deferiprone/therapeutic use , Deferoxamine/therapeutic use , Iron Chelating Agents/therapeutic use , Iron Overload/drug therapy , beta-Thalassemia/drug therapy , Administration, Oral , Adult , Blood Transfusion , Chelation Therapy , Deferasirox/administration & dosage , Deferiprone/administration & dosage , Deferoxamine/administration & dosage , Drug Therapy, Combination , Female , Humans , Iron/isolation & purification , Iron/urine , Iron Chelating Agents/administration & dosage , Iron Overload/complications , Iron Overload/urine , Male , Pilot Projects , Young Adult , beta-Thalassemia/complications , beta-Thalassemia/urineABSTRACT
BACKGROUND: Iron chelation therapy is one of the mainstays of the management of the patients with ß-thalassemia (BT) major. Deferasirox is an oral active iron chelating agent. Proteinuria is one of the potential renal adverse effects of deferasirox, and monthly follow-up for proteinuria is suggested by Food and Drug Administration and European Medicine Agency. METHODS: We aimed to investigate the necessity for monthly monitoring for proteinuria among patients with BT on deferasirox. A retrospective laboratory and clinic data review was performed for patients with BT major or intermedia who were treated with deferasirox chelation therapy. All patients were monitored for proteinuria for every 3 or 4 weeks after the initiation of deferasirox with serum creatinine and spot urine protein/creatinine ratios. RESULTS: The median follow-up time of the 37 (36 BT major and one BT intermedia) patients was 44 months. Seven patients (18.9%) developed significant proteinuria (ratio ≥0.8). Of the 1490 measurements, 12 tests (0.8%) were proteinuric. Urine proteinuria resolved in all of the patients during the follow-up. The risk of proteinuria was higher at ages below a cut-off point of 23 years (p = 0.019). Patients, who were on deferasirox at doses above a cut-off dose of 29â mg/kg/day, were found to have higher risk of proteinuria development (p = 0.004). CONCLUSION: Proteinuria resolves without any complication or major intervention according to our results. Potentially more risky groups (age below 23 years old and receivers above a dose of 29â mg/kg/day) might be suggested to be followed monthly, besides monitoring all of the patients.
Subject(s)
Benzoates/adverse effects , Proteinuria/urine , Triazoles/adverse effects , beta-Thalassemia/drug therapy , beta-Thalassemia/urine , Adolescent , Adult , Benzoates/therapeutic use , Child , Child, Preschool , Deferasirox , Female , Humans , Male , Proteinuria/chemically induced , Proteinuria/diagnosis , Retrospective Studies , Triazoles/therapeutic use , Young Adult , beta-Thalassemia/bloodABSTRACT
BACKGROUND: The aim of this study was to investigate novel urinary biomarkers including N-acetyl-ß-D-glucosaminidase (NAG), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and liver-type fatty acid binding protein (L-FABP) in children with ß-thalassemia major (ß-TM). MATERIALS AND METHODS: Totally, 52 patients (29 boys, 23 girls) with ß-TM and 29 healthy controls (3-17 years) were included. Various demographic characteristics and blood transfusions/year, disease duration, and chelation therapy were recorded. Serum urea, creatinine, electrolytes, and ferritin and urinary creatinine, protein, calcium, phosphorus, sodium, potassium, and uric acid in first morning urine samples were measured and estimated glomerular filtration rate (eGFR) was calculated. Routine serum and urinary biochemical variables, urinary NAG to Creatinine (U(NAG/Cr)), U(NGAL/Cr), U(KIM-1/Cr), and U(L-FABP/Cr) ratios were determined. RESULTS: Patients had similar mean serum urea, creatinine and eGFR levels compared with controls (p > 0.05 for all). The mean urinary protein to creatinine (U(Protein/Cr)) ratio was significantly higher in patients compared to the healthy subjects (0.13 ± 0.09 mg/mg and 0.07 ± 0.04 mg/mg, respectively; p < 0.001). Significantly increased U(NAG/Cr) (0.48 ± 0.58 vs. 0.23 ± 0.16, p = 0.026) and U(NGAL/Cr) (22.1 ± 18.5 vs. 11.5 ± 6.17, p = 0.01) ratios were found in ß-TM patients compared with healthy controls. However, no differences were found in serum and urinary electrolytes or U(KIM-1/Cr) and U(L-FABP/Cr) ratios between patients and controls (p > 0.05). Significant correlations were found between urinary biomarkers and urinary electrolytes (p < 0.05). CONCLUSIONS: Our results suggest that urinary NAG and NGAL may be considered to be reliable markers to monitor renal injury in ß-TM patients.
Subject(s)
Acute Kidney Injury/etiology , Acute Kidney Injury/urine , beta-Thalassemia/complications , beta-Thalassemia/urine , Adolescent , Biomarkers/urine , Child , Child, Preschool , Cross-Sectional Studies , Female , Humans , MaleABSTRACT
BACKGROUND: Beta thalassemia major is a lifelong transfusion-dependent disorder. Transfusion-dependent thalassemia patients are prone to develop renal dysfunction due to iron overload, chronic anemia, and/or chelation therapy. METHODS: In this prospective study, thalassemia patients who fitted inclusion and exclusion criteria received Deferasirox 20 mg/kg/day. A complete biochemistry analysis of serum and 24-hour-urine specimens was performed before and after treatment. Estimated glomerular filtration rate (eGFR), Fractional excretion of sodium (FENA), potassium (FEK), uric acid (FEUA), and the maximum ratio of tubular reabsorption of phosphorus to eGFR (TmP/GFR) at baseline and after treatment was calculated and compared. RESULTS: A total of 30 patients with mean age of 4.9 ± 3.2 years were recruited. The mean serum creatinine increased significantly after 6 months of treatment (0.54 ± 0.08 vs. 0.67 ± 0.16, P < .001) while eGFR was decreased (104.36 ± 19.62 vs. 86.00 ± 16.92, P < .001). Mean potassium level in serum was increased after treatment, while serum calcium, magnesium, and uric acid levels decreased significantly (P > .05). A significant increase was confirmed for mean urinary ß2-microglobulin (ß2-MG), protein, uric acid, calcium, and magnesium (P > .05). CONCLUSION: Our findings highlighted tubular nephropathy induced by Deferasirox in patients with beta thalassemia, and confirmed the necessity for diligent monitoring of renal function in thalassemia patients receiving Deferasirox.
Subject(s)
Benzoates/adverse effects , Iron Chelating Agents/adverse effects , Iron Overload/drug therapy , Kidney Diseases/chemically induced , Triazoles/adverse effects , beta-Thalassemia/therapy , Adolescent , Benzoates/administration & dosage , Blood Transfusion , Child , Child, Preschool , Creatinine/blood , Creatinine/urine , Deferasirox , Female , Glomerular Filtration Rate/drug effects , Humans , Iron Chelating Agents/administration & dosage , Iron Overload/blood , Iron Overload/etiology , Iron Overload/urine , Kidney Diseases/blood , Kidney Diseases/physiopathology , Kidney Diseases/urine , Male , Metals/blood , Metals/urine , Prospective Studies , Triazoles/administration & dosage , beta-Thalassemia/blood , beta-Thalassemia/physiopathology , beta-Thalassemia/urineABSTRACT
Dose-related pharmacokinetics and urinary iron excretion (UIE) of an orally active iron chelator, deferiprone (L1), was investigated in 12 severe ß-thalassemia/hemoglobin E patients. The patients received two single doses of 25 and 50 mg/kg with a 2-week washout period. Deferiprone was rapidly absorbed and reached maximum concentration (C(max)) within 1 h after administration. Pharmacokinetic parameters including C(max) and area under concentration time curve from time zero to infinity (AUC(0-∞)) as well as urinary excretion of non-conjugated and glucuronide-conjugated deferiprone (L1 and L1-G) increased proportionally with the dose of deferiprone. A constant ratio of AUC(0-∞) of L1-G to L1 and a percentage of urinary excretion of L1-G indicated that increasing the dosage does not influence deferiprone biotransformation. Longer terminal elimination half-lifeand higher volume of distribution of L1 were observed with the high dose and correlated with deferiprone-chelated iron in serum. Unexpectedly, UIE did not show a linear relationship with the increased dose of deferiprone. The correlation between UIE and creatinine clearance suggested the possibility of L1-iron complex redistribution in patients with renal impairment treated with high-dose deferiprone.
Subject(s)
Iron Chelating Agents/pharmacokinetics , Iron/urine , Pyridones/pharmacokinetics , beta-Thalassemia/urine , Adolescent , Adult , Area Under Curve , Deferiprone , Female , Glucuronides/urine , Hemoglobin E , Humans , Male , Middle Aged , Pyridones/urine , Young AdultABSTRACT
BACKGROUND: Plasma non-transferrin bound iron refers to heterogeneous plasma iron species, not bound to transferrin, which appear in conditions of iron overload and ineffective erythropoiesis. The clinical utility of non-transferrin bound iron in predicting complications from iron overload, or response to chelation therapy remains unproven. We undertook carefully timed measurements of non-transferrin bound iron to explore the origin of chelatable iron and to predict clinical response to deferiprone. DESIGN AND METHODS: Non-transferrin bound iron levels were determined at baseline and after 1 week of chelation in 32 patients with thalassemia major receiving deferiprone alone, desferrioxamine alone, or a combination of the two chelators. Samples were taken at baseline, following a 2-week washout without chelation, and after 1 week of chelation, this last sample being taken 10 hours after the previous evening dose of deferiprone and, in those receiving desferrioxamine, 24 hours after cessation of the overnight subcutaneous infusion. Absolute or relative non-transferrin bound iron levels were related to transfusional iron loading rates, liver iron concentration, 24-hour urine iron and response to chelation therapy over the subsequent year. RESULTS: Changes in non-transferrin bound iron at week 1 were correlated positively with baseline liver iron, and inversely with transfusional iron loading rates, with deferiprone-containing regimens but not with desferrioxamine monotherapy. Changes in week 1 non-transferrin bound iron were also directly proportional to the plasma concentration of deferiprone-iron complexes and correlated significantly with urine iron excretion and with changes in liver iron concentration over the next 12 months. CONCLUSIONS: The widely used assay chosen for this study detects both endogenous non-transferrin bound iron and the iron complexes of deferiprone. The week 1 increments reflect chelatable iron derived both from liver stores and from red cell catabolism. These increments correlate with urinary iron excretion and the change in liver iron concentration over the subsequent year thus predicting response to deferiprone-containing chelation regimes. This clinical study was registered at clinical.trials.gov with the number NCT00350662.
Subject(s)
Chelation Therapy , Deferoxamine/therapeutic use , Iron Chelating Agents/therapeutic use , Iron Overload/drug therapy , Pyridones/therapeutic use , beta-Thalassemia/drug therapy , Adolescent , Blood Proteins/metabolism , Blood Transfusion , Child , Deferiprone , Deferoxamine/administration & dosage , Drug Administration Schedule , Humans , Iron/blood , Iron/urine , Iron Chelating Agents/administration & dosage , Iron Overload/blood , Iron Overload/urine , Liver/metabolism , Longitudinal Studies , Protein Binding , Pyridones/administration & dosage , Young Adult , beta-Thalassemia/blood , beta-Thalassemia/urineABSTRACT
There are limited studies on renal involvement in beta-thalassemia, mainly involving patients on deferoxamine, reporting both glomerular and tubular dysfunction. The aim of the present study was to investigate renal involvement in young thalassemia patients, using both conventional and early markers of renal dysfunction, and to correlate findings to iron chelation therapy. Forty-two patients aged 4-23 years were studied and, for analysis purposes, were divided into two groups based on chelation therapy (group A receiving deferasirox and group B receiving deferoxamine and deferiprone combination therapy). In addition to conventional renal biochemistries, creatinine clearance, estimated glomerular filtration rate, serum cystatin C (Cys C), fractional excretion of sodium, tubular phosphorus reabsorption and urine calcium, protein, beta(2)-microglobulin (beta(2)-MG) and glucose levels were measured. A considerable number of patients demonstrated impaired renal function with elevated Cys C levels (36%), glomerular dysfunction with proteinuria (24%) and tubulopathy with hypercalciuria (35.5%) and elevated excretion of beta(2)-MG (33.5%). Renal involvement seems to be present even in young patients with beta-thalassemia, therefore, routine use of early markers of renal dysfunction is recommended. Further studies are needed in order to investigate the role of new chelators in tubular function parameters.
Subject(s)
Benzoates/adverse effects , Deferoxamine/adverse effects , Iron Chelating Agents/adverse effects , Kidney Diseases/complications , Pyridones/adverse effects , Triazoles/adverse effects , beta-Thalassemia/drug therapy , Adolescent , Adult , Benzoates/therapeutic use , Biomarkers/blood , Biomarkers/urine , Chelation Therapy/adverse effects , Child , Child, Preschool , Cystatin C/blood , Deferasirox , Deferiprone , Deferoxamine/therapeutic use , Drug Therapy, Combination , Early Diagnosis , Female , Humans , Hypercalciuria , Iron Chelating Agents/therapeutic use , Kidney Diseases/blood , Kidney Diseases/chemically induced , Kidney Diseases/urine , Kidney Function Tests , Male , Proteinuria , Pyridones/therapeutic use , Triazoles/therapeutic use , Young Adult , beta 2-Microglobulin/urine , beta-Thalassemia/blood , beta-Thalassemia/complications , beta-Thalassemia/urineABSTRACT
BACKGROUND AND OBJECTIVES: The aim of this prospective, randomized, 1-year study was to compare the efficacy and safety of oral deferiprone (DFP) with those of combinations of parenteral desferrioxamine (DFO) with oral DFP. DESIGN AND METHODS: A total of 24 patients with thalassemia major were randomized to receive one of the following two treatments; DFP given at a daily dose of 75 mg/kg in combination with DFO (40-50 mg/kg twice weekly) (n=12) or as single agent (n=12). In addition, 12 patients treated with 40-50 mg/kg DFO 5 days weekly were included as a reference group without randomization. Changes in liver iron concentration (LIC) and serum ferritin (SF) were assessed; total iron excretion (TIE), urinary iron excretion (UIE) and iron balance were calculated. Cardiac function and toxicity were also examined. DESIGN AND METHODS: SF and LIC were significantly reduced after 1 year of combination therapy (p=0.01 and 0.07, respectively). A decrease of LIC was observed in all but one patient (87.5%) following the combination therapy but in only 42% of patients treated with DFP monotherapy. In the DFO reference group, a statistically significant decrease in LIC (p=0.01) associated with a substantial decrease in SF (p=0.08) was observed after 1 year. The combination regimen resulted in greater TIE compared to DFP monotherapy (p=0.08) and was the regimen associated with the highest iron balance compared to DFP monotherapy (p=0.04) or standard DFO treatment (p=0.006). INTERPRETATIONS AND CONCLUSIONS: The addition of subcutaneous DFO twice weekly to oral DFP 75 mg/kg is a highly efficacious and safe chelation therapy providing superior chelation activity to that of DFP and likely has an efficacy profile comparable to that of standard DFO.
Subject(s)
Deferoxamine/administration & dosage , Pyridones/administration & dosage , Siderophores/administration & dosage , beta-Thalassemia/drug therapy , Adolescent , Adult , Child , Deferiprone , Female , Ferritins/blood , Humans , Iron/blood , Iron/urine , Liver/metabolism , Male , Time Factors , beta-Thalassemia/blood , beta-Thalassemia/urineABSTRACT
The most widely used drug for iron chelation is deferoxamine (DFO) mesylate. While effective in promoting iron excretion, it requires prolonged daily infusions, often resulting in poor compliance. A clinical trial was conducted using starch-conjugated DFO (S-DFO; 40SD02), a high-molecular-weight iron chelator possessing prolonged vascular retention. Single doses of S-DFO were infused intravenously into groups of four transfusion-dependent patients with beta-thalassaemia at doses of 150, 300, 600 and 900 mg/kg. Urinary iron excretion and various pharmacologic parameters were evaluated for 1 week and safety for 3 weeks. No drug-related effects were observed on clinical chemistries, haematological and coagulation parameters, urinalyses, vital signs or electrocardiograms. Drug-related adverse events were limited to four urticarial reactions, none requiring termination of the infusion. The drug stimulated clinically significant urinary iron excretion, with the highest dose (900 mg/kg) inducing excretion of 1.31 mg of iron/kg (range 0.79-1.90 mg/kg) over 1 week, with residual iron-binding capacity present in the plasma for over 6 d. In summary, treatment with S-DFO, administered weekly, has the potential to achieve iron balance in the poorly compliant patient.
Subject(s)
Chelation Therapy/methods , Deferoxamine/therapeutic use , Iron Chelating Agents/therapeutic use , beta-Thalassemia/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Infusions, Intravenous , Iron/blood , Iron/urine , Male , Middle Aged , Prospective Studies , beta-Thalassemia/blood , beta-Thalassemia/urineABSTRACT
A prospective multi-centric study was conducted to determine if iron-chelating agent deferiprone also chelates zinc. Twenty four-hour urinary zinc levels were compared in multiply transfused children with thalassemia major not receiving any chelation therapy (Group A, n = 28), those receiving deferiprone (Group B, n = 30) and age and sex-matched controls of subjects in Group B (Group C, n = 29) by a colorimetric method. The 24-hour mean urinary excretion of zinc was significantly higher in Group B than in the other two groups indicating that deferiprone chelates zinc.
Subject(s)
Iron Chelating Agents/therapeutic use , Pyridones/therapeutic use , Zinc/urine , beta-Thalassemia/urine , Blood Transfusion , Child , Child, Preschool , Deferiprone , Female , Humans , Male , Prospective Studies , Retreatment , Time Factors , beta-Thalassemia/therapySubject(s)
Chelation Therapy , Deferoxamine/therapeutic use , Iron Chelating Agents/therapeutic use , Iron Overload/drug therapy , Iron/urine , Pyridones/therapeutic use , Transfusion Reaction , beta-Thalassemia/urine , Adolescent , Adult , Combined Modality Therapy , Deferiprone , Deferoxamine/administration & dosage , Deferoxamine/pharmacokinetics , Drug Therapy, Combination , Female , Humans , Iron Chelating Agents/administration & dosage , Iron Chelating Agents/pharmacokinetics , Iron Overload/etiology , Iron Overload/urine , Male , Pyridones/administration & dosage , Pyridones/pharmacokinetics , Splenectomy , Tissue Distribution , Treatment Outcome , beta-Thalassemia/surgery , beta-Thalassemia/therapyABSTRACT
The purpose of the present study was to identify noninvasive methods to evaluate the severity of iron overload in transfusion-dependent beta-thalassemia and the efficiency of intensive intravenous therapy as an additional tool for the treatment of iron-overloaded patients. Iron overload was evaluated for 26 beta-thalassemia homozygous patients, and 14 of them were submitted to intensive chelation therapy with high doses of intravenous deferoxamine (DF). Patients were classified into six groups of increasing clinical severity and were divided into compliant and non-compliant patients depending on their adherence to chronic chelation treatment. Several methods were used as indicators of iron overload. Total gain of transfusion iron, plasma ferritin, and urinary iron excretion in response to 20 to 60 mg/day subcutaneous DF for 8 to 12 h daily are useful to identify iron overload; however, urinary iron excretion in response to 9 g intravenous DF over 24 h and the increase of urinary iron excretion induced by high doses of the chelator are more reliable to identify different degrees of iron overload because of their correlation with the clinical grades of secondary hemochromatosis and the significant differences observed between the groups of compliant and non-compliant patients. Finally, the use of 3-9 g intravenous DF for 6-12 days led to a urinary iron excretion corresponding to 4.1 to 22.4% of the annual transfusion iron gain. Therefore, continuous intravenous DF at high doses may be an additional treatment for these patients, as a complement to the regular subcutaneous infusion at home, but requires individual planning and close monitoring of adverse reactions.
Subject(s)
Chelation Therapy/methods , Deferoxamine/therapeutic use , Iron Chelating Agents/therapeutic use , Iron Overload/drug therapy , Iron/urine , beta-Thalassemia/urine , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Infusions, Intravenous , Male , Middle Aged , Multivariate Analysis , Patient Compliance , Severity of Illness Index , Transfusion Reaction , beta-Thalassemia/therapyABSTRACT
It has been reported that iron overload in beta-thalassemia leads to an enhanced generation of reactive oxygen species and to oxidative stress. We have studied the oxidant/antioxidant imbalance in the blood of 48 transfusion-dependent beta-thalassemic patients (TLP) (17 males, 31 females, 11-22 year), under chelation therapy, and in 40 sex and age matched healthy controls (CTR). Plasma and lymphocyte levels of vitamin E (Vit E), ubiquinol (CoQ10H2), ubiquinone (CoQ10), plasma concentrations of vitamin A (Vit A), beta-carotene, lycopene, vitamin C (Vit C), total thiols, fatty acid patterns of phospholipids (PL-FA), and plasma and urinary markers of lipoperoxidation (TBA-RM, conjugated dienes, and azelaic acid (AZA), as well as the urinary levels of catecholamine and serotonin metabolites, were evaluated by gas chromatography-mass spectrometry (GC-MS), HPLC and spectrophotometry. Routine laboratory blood analyses were performed on the same samples; 39/48 TLP were HCV positive. Blood samples were collected just before transfusion, the 24 h urine samples the day before. Our results clearly showed that a severe oxidative stress occurs in the plasma of TLP in comparison with CTR. In fact, the levels of lipophilic antioxidants and ascorbate were severely depleted: CoQ10H2 (-62.5%), total CoQ10 (-35.1%), Vit E (-43.8%), beta-carotene (-31.1%), lycopene (-63.7%), Vit A (-35.9%), Vit C (-23.1%). The impairment of the antioxidant status was associated with elevated plasma levels of by-products of lipoperoxidation and urinary concentrations of catecholamine metabolites and of AZA, indicating a high degree of both neurological stress and lipoperoxidation. A significant positive correlation was found between vitamin E and non-transferrin-bound iron (NTBI) (r = -0.81; p < 0.001), while no correlation was found between antioxidant depletion and ferritin serum levels, average blood consumption, or the presence of clinical complications. The administration of selective antioxidants along with an appropriate diet might represent a promising way of counteracting oxidative damage and its deleterious effects on the progression of the disease.
Subject(s)
Antioxidants/analysis , Catecholamines/urine , beta-Thalassemia/metabolism , Adolescent , Adult , Bilirubin/blood , Carotenoids/blood , Catecholamines/metabolism , Child , Fatty Acids/blood , Fatty Acids/metabolism , Female , Ferritins/blood , Humans , Iron/blood , Lipid Peroxidation , Male , Oxidative Stress , Serotonin/metabolism , Serotonin/urine , Sulfhydryl Compounds/blood , Ubiquinone/analogs & derivatives , Ubiquinone/blood , Uric Acid/blood , Vitamins/blood , beta-Thalassemia/blood , beta-Thalassemia/urineABSTRACT
Nineteen transfusion-dependent beta-thalassemia major patients were included in the study. Six of these patients underwent chelation therapy with desferrioxamine by subcutaneous infusion (50 mg/kg/12 hr) and 13 received intravenous infusion (50 mg/kg/6 hr or 100 mg/kg/24 hr). BUN, creatinine, creatinine clearance, beta 2-microglobulin, urinary beta 2-microglobulin and urinary growth hormone excretion were evaluated during desferrioxamine treatment. Thirteen out of nineteen patients presented tubular damage indicated by increased excretion of urinary beta 2-microglobulin. 85% (11 of 13) of these patients showed more serious tubular damage, as demonstrated by concurrent increased urinary growth hormone excretion. Moreover, a positive correlation between urinary growth hormone excretion and urinary beta 2-microglobulin was observed (P < 0.05).
Subject(s)
Deferoxamine/adverse effects , Kidney Diseases/chemically induced , Kidney Diseases/diagnosis , beta-Thalassemia/therapy , Administration, Cutaneous , Adolescent , Adult , Child , Child, Preschool , Deferoxamine/administration & dosage , Deferoxamine/therapeutic use , Enzyme-Linked Immunosorbent Assay , Female , Growth Hormone/urine , Humans , Immunoradiometric Assay , Infusions, Intravenous , Kidney Function Tests , Male , beta 2-Microglobulin/urine , beta-Thalassemia/urineABSTRACT
This study has been undertaken to find out whether urinary zinc excretion, which is already increased in patients with thalassemia, is further increased by usual and high doses of desferrioxamine (DF). A total of 11 beta-thalassemia major patients were included. DF infusions have been performed with doses, either 50 mg/kg or 150 mg/kg. Nine age and sex matched normal children were taken as the control group. The mean basal-Zn excretion of the patients was significantly higher than the mean Zn excretion observed in controls. No significant difference is observed between the mean Zn excretion obtained on different doses of DF. However, they are both significantly higher than the mean basal-Zn levels of the controls.